ValuEngine lowered shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a research report sent to investors on Friday morning.
PURE Bioscience (OTCMKTS PURE) traded down $0.06 during trading hours on Friday, reaching $1.00. The company’s stock had a trading volume of 86,939 shares, compared to its average volume of 38,676. PURE Bioscience has a 12 month low of $0.75 and a 12 month high of $1.36.
TRADEMARK VIOLATION WARNING: “PURE Bioscience (PURE) Downgraded to “Sell” at ValuEngine” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/11/pure-bioscience-pure-downgraded-to-sell-at-valuengine.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.